Dr. John Trimble, MD

Otolaryngology Acworth, GA Male
NPI: 1457416570
Total Payments
$6,249
2022 Payments
$2,454
Companies
2
Transactions
50

Payment Breakdown by Category

Research$5,000 (80.0%)
Travel$774.13 (12.4%)
Food & Beverage$475.45 (7.6%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $5,000 39 80.0%
Travel and Lodging $774.13 5 12.4%
Food and Beverage $475.45 6 7.6%

Payments by Type

Research
$5,000
39 transactions
General
$1,250
11 transactions

Top Paying Companies

Company Total Records Latest Year
GlaxoSmithKline, LLC. $5,000 39 $0 (2022)
Novartis Pharmaceuticals Corporation $1,250 11 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2022 $2,454 12 GlaxoSmithKline, LLC. ($2,454)
2020 $1,300 14 GlaxoSmithKline, LLC. ($1,300)
2018 $1,246 13 GlaxoSmithKline, LLC. ($1,246)
2017 $1,250 11 Novartis Pharmaceuticals Corporation ($1,250)

All Payment Transactions

50 individual payment records from CMS Open Payments — Page 2 of 2

Date Company Product Nature Form Amount Type
01/07/2020 GlaxoSmithKline, LLC. NUCALA (Biological) — In-kind items and services $24.23 Research
Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY
06/07/2018 GlaxoSmithKline, LLC. — — Cash or cash equivalent $146.63 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
06/07/2018 GlaxoSmithKline, LLC. — — Cash or cash equivalent $27.16 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $311.76 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $284.78 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $124.47 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $120.54 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $50.07 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $49.34 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $34.39 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $34.33 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $27.37 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $26.83 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
05/15/2018 GlaxoSmithKline, LLC. — — In-kind items and services $7.97 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST
08/28/2017 Novartis Pharmaceuticals Corporation FEVIPIPRANT (Drug) Food and Beverage In-kind items and services $12.23 General
04/07/2017 Novartis Pharmaceuticals Corporation — Food and Beverage In-kind items and services $133.27 General
04/07/2017 Novartis Pharmaceuticals Corporation — Food and Beverage Cash or cash equivalent $75.00 General
04/07/2017 Novartis Pharmaceuticals Corporation — Travel and Lodging Cash or cash equivalent $45.51 General
04/07/2017 Novartis Pharmaceuticals Corporation — Travel and Lodging Cash or cash equivalent $19.50 General
04/06/2017 Novartis Pharmaceuticals Corporation — Travel and Lodging In-kind items and services $590.64 General
04/06/2017 Novartis Pharmaceuticals Corporation — Food and Beverage In-kind items and services $125.00 General
04/06/2017 Novartis Pharmaceuticals Corporation — Food and Beverage In-kind items and services $118.87 General
04/06/2017 Novartis Pharmaceuticals Corporation — Travel and Lodging Cash or cash equivalent $98.98 General
04/06/2017 Novartis Pharmaceuticals Corporation — Travel and Lodging In-kind items and services $19.50 General
04/06/2017 Novartis Pharmaceuticals Corporation — Food and Beverage Cash or cash equivalent $11.08 General
«12

Research Studies & Clinical Trials

Study Name Company Amount Records
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT GlaxoSmithKline, LLC. $3,754 26
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST GlaxoSmithKline, LLC. $1,246 13

About Dr. John Trimble, MD

Dr. John Trimble, MD is a Otolaryngology healthcare provider based in Acworth, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457416570.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Trimble, MD has received a total of $6,249 in payments from pharmaceutical and medical device companies, with $2,454 received in 2022. These payments were reported across 50 transactions from 2 companies. The most common payment nature is "" ($5,000).

Practice Information

  • Specialty Otolaryngology
  • Location Acworth, GA
  • Active Since 12/27/2006
  • Last Updated 11/19/2011
  • Taxonomy Code 207Y00000X
  • Entity Type Individual
  • NPI Number 1457416570

Products in Payments

  • NUCALA (Biological) $3,754
  • FEVIPIPRANT (Drug) $12.23

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.